Table 3 Summary scores (baseline) and change scores for primary and secondary outcome variables.
| Â | Quetiapine | Placebo |
|---|---|---|
YBOCS (baseline) | 26.4 (SD4.6) | 27.7(SD3.9) |
YBOCS (change at week 6) | -7.1(SD7.2) | -7.2(SD8.4) |
YBOCS % change | -26.9% | -26% |
CGI-Severity (baseline) | 5.2 (SD0.8) | 5.3 (SD0.8) |
CGI-Severity (week 6) | 4.1 (SD1.4) | 4.1(SD1.5) |
MADRS (baseline) | 10.6 (SD 4.8) | 10.71 (SD 9.8) |
MADRS (change at week 6) | -2.6 (SD 6.5) | -3 (SD 8.3) |
SDS (baseline) | 17.9 (SD 5.3) | 19.6(SD4.7) |
SDS (change at week 6) | -5.3(SD5.6) | -6.1 (SD4.8) |
YGTSS (baseline) | 24.7 (SD 19.3) | 22.6(SD 22.3) |
YGTSS (change at week 6) | -4.5(SD 5.1) | -9.4 (SD 14.6) |
YGTSS % change | -18.2% | -41.6% |